Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Advent International

This page shows the latest Advent International news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca blocks take-private buyout of Sobi

AstraZeneca blocks take-private buyout of Sobi

The $7.6bn takeover of Swedish rare disease company Sobi by private equity group Advent International and Singapore’s wealth fund failed to convince the 90% of shareholders needed. ... One of the world’s biggest private equity firms, Advent

Latest news

  • Private equity firms agree deal to take over Stada Private equity firms agree deal to take over Stada

    Cinven and Bain Capital beat out competition from Advent International. The board of German pharma company Stada has agreed to a takeover deal with two of three interested private equity companies, ... Cinven and Bain Capital made what Stada said was the

  • Stada opens books to let formal bidding commence Stada opens books to let formal bidding commence

    Cinven, Advent International and Bain Capital now have opportunity to revise their bids. ... The three interested parties - confirmed as Cinven, Advent International and Bain Capital - will now all receive the "same level of information" and so have the

  • Advent tops Cinven offer for Stada as third suitor looms Advent tops Cinven offer for Stada as third suitor looms

    Private equity firm Advent International has topped an earlier bid from rival Cinven for Stada and matched an offer from an undisclosed third party. ... needs to develop a new culture in order to succeed on the international stage.

  • UCB to sell its US generics business for $1.5bn UCB to sell its US generics business for $1.5bn

    Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals. ... The buyers are Advent International and Avista Capital Partners, both private equity firms with a healthcare focus.

  • GSK plans to sell off older products GSK plans to sell off older products

    conference. Among the firms given the opportunity to view the portfolio are Advent International, Blackstone and KKR, according to Reuters, which indicated the overture was initially revealed by Sky News.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Earlier in the month the private equity (PE) firm Cinven offered 56 a share to acquire Stada but this has been topped by a binding offer from another PE company, Advent ... International Corporation, for 58 a share valuing the company at 3.6bn ($3.8bn).

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    UCB (Kremers Urban Pharma) /Advent International and Avista Capital Partners. Generics portfolio.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Similarly UCB is understood to be selling its highly profitable generics business Kremers Urban Pharmaceuticals to Advent International and Avista Capital Partners for $1.53bn to allow it to focus on ... Bridget brings to the Medius Associates team her

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • 101translations

    With the advent of the internet, international communication has become the norm, with people reaching out globally.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links